Entera Bio stock analysis
Entera Bio (5DT) Stock Price & Analysis
5DT Stock Chart & Stats
- Day’s Range
- EUR 2.86 - EUR 2.86
- 52-Week Range
- EUR 0.84 - EUR 3.46
- Previous Close
- EUR 2.80
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 491.28M
- Enterprise Value
- EUR 150.15M
- Total Cash (Recent Filing)
- EUR 265.88M
- Total Debt (Recent Filing)
- EUR 397.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.68
- Next Earnings
- Mar 26, 2027 (Est.)
- EPS Estimate
- -0.15
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage gives Entera substantial balance-sheet flexibility relative to its development-stage operations. The reported equity and asset base can support continued clinical investment and reduce near-term debt-service pressure, although the company still must convert capital into durable operating progress.
EB613 Phase 3 Readiness
Regulatory alignment on a defined Phase 3 design materially advances EB613 toward a pivotal development milestone. A clear trial path can focus resources, improve execution planning, and establish a stronger basis for evaluating the oral osteoporosis candidate over the next several quarters.
Broad Oral Peptide Pipeline
Multiple programs extend the value of Entera’s oral peptide platform beyond one asset. Progress in hypoparathyroidism and metabolic disease creates additional clinical catalysts and diversification, while the OPKO collaboration provides a structured route for advancing EB612 toward human studies.
Bears Say
Minimal Revenue And Persistent Losses
Entera has not established recurring product revenue, and substantial operating losses continue despite the recent TTM net-income improvement. This leaves results dependent on development progress and non-operating items rather than a proven commercial engine, limiting earnings durability over the medium term.
Ongoing Cash Burn
Persistent negative operating cash flow shows that Entera’s research programs have not yet become self-funding. Although TTM cash flow is near break-even, the pack describes it as volatile and not supported by durable operating profitability, leaving future development reliant on available capital.
External Funding Dependence
Because Entera lacks an approved commercial product, advancing its pipeline depends on cash reserves, collaborations, or additional financing rather than recurring sales. This capital-dependent model can make long-term execution sensitive to funding needs, while higher R&D spending increases the resources required.
Entera Bio News
5DT FAQ
What was Entera Bio’s price range in the past 12 months?
What is Entera Bio’s market cap?
When is Entera Bio’s upcoming earnings report date?
How were Entera Bio’s earnings last quarter?
Is Entera Bio overvalued?
Does Entera Bio pay dividends?
What is Entera Bio’s EPS estimate?
How many shares outstanding does Entera Bio have?
What happened to Entera Bio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Entera Bio?
What is the TipRanks Smart Score and how is it calculated?
Entera Bio Stock Smart Score
Company Description
Entera Bio
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Miranda J. Toledano
- Employees
- 27
- Website
- www.enterabio.com
- Address
- Kiryat Hadassah Minrav Building, Jerusalem, JM, 9112002, IL
Entera Bio (5DT) Earnings & Revenues
5DT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 4 |
| Technical Analysis | 3 | 2 | 4 |
| Moving Averages | 12 | 0 | 0 |














